Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of the National Cancer Institute

• Publication date

  2012-10-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/jnci/djs377PMID 22984202PMCID PMC3529616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of mouse models to study plasminogen activator inhibitor-1.

  2011cited by this paper
• Unimpeded skin carcinogenesis in K14‐HPV16 transgenic mice deficient for plasminogen activator inhibitor

  2011cited by this paper
• Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

  2011cited by this paper
• Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel

  2011cited by this paper
• The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling

  2010cited by this paper
• Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors

  2010cited by this paper
• Biochemical properties of plasminogen activator inhibitor-1.

  2009cited by this paper
• Low Density Lipoprotein Receptor-related Protein 1 Promotes Anti-apoptotic Signaling in Neurons by Activating Akt Survival Pathway*

  2009cited by this paper
• Role of fibrinolysis in obesity and thrombosis.

  2009cited by this paper
• The Impact of the Fibrinolytic System on the Risk of Venous and Arterial Thrombosis

  2009cited by this paper
• Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice.

  2008cited by this paper
• Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis

  2008cited by this paper
• Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.

  2008cited by this paper
• Evolving role of uPA/uPAR system in human cancers.

  2008cited by this paper
• Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1)

  2008cited by this paper
• Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.

  2008cited by this paper
• Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.

  2008cited by this paper
• Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

  2007cited by this paper
• Matrix metalloproteinases and the regulation of tissue remodelling

  2007cited by this paper
• In search of partners: linking extracellular proteases to substrates

  2007cited by this paper
• The Plasminogen Activator System and Cancer

  2007cited by this paper
• Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.

  2007cited by this paper
• Mechanism of Inactivation of Plasminogen Activator Inhibitor-1 by a Small Molecule Inhibitor*

  2007cited by this paper
• Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

  2007cited by this paper
• A guide to murine fibrinolytic factor structure, function, assays, and genetic alterations

  2007cited by this paper
• Activity-based Protein Profiling Implicates Urokinase Activation as a Key Step in Human Fibrosarcoma Intravasation*

  2006cited by this paper
• Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1

  2006cited by this paper
• Effect of pharmacologic plasminogen activator inhibitor‐1 inhibition on cell motility and tumor angiogenesis

  2006cited by this paper
• Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis

  2005cited by this paper
• Plasminogen activation and cancer

  2005cited by this paper
• Indication of a role of plasminogen activator inhibitor type 1 in protecting murine fibrosarcoma cells against apoptosis

  2005cited by this paper
• Inhibition of apoptosis and caspase‐3 in vascular smooth muscle cells by plasminogen activator inhibitor type‐1

  2004cited by this paper
• Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

  2004cited by this paper
• Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth

  2004cited by this paper
• The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1*

  2004cited by this paper
• [Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer].

  2004cited by this paper
• Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

  2003cited by this paper
• Computerized Quantification of Tissue Vascularization Using High-resolution Slide Scanning of Whole Tumor Sections

  2003cited by this paper
• Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice

  2003cited by this paper
• The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

  2002cited by this paper
• Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms

  2002cited by this paper
• Plasmin/Plasminogen System in Colorectal Cancer

  2002cited by this paper
• Serpins (Serine Protease Inhibitors)

  2001cited by this paper
• Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.

  2001cited by this paper
• Short tandem repeat profiling provides an international reference standard for human cell lines

  2001cited by this paper
• Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours

  2001cited by this paper
• Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

  2000cited by this paper
• Methods of Blood Collection in the Mouse

  2000cited by this paper
• Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

  2000cited by this paper
• Keeping health and safety first.

  2000cited by this paper
• Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse

  1999cited by this paper
• Plasminogen activator inhibitor‐1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients

  1998cited by this paper
• Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.

  1998cited by this paper
• Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

  1998cited by this paper
• Prognostic factors in gastric cancer

  1997cited by this paper
• ECM and cell surface proteolysis: regulating cellular ecology.

  1997cited by this paper
• Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.

  1997cited by this paper
• ECM and Cell Surface Proteolysis: Minireview Regulating Cellular Ecology

  1997cited by this paper
• Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

  1995cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.

  1993cited by this paper
• Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

  1990cited by this paper
• Urokinase-dependent cell surface proteolysis and cancer.

  1990cited by this paper
• Plasminogen activator activity and molecular weight patterns in human brain tumors.

  1988cited by this paper
• © 1999 Cancer Research Campaign Article no. bjoc.1998.0278 Prognostic significance of urokinase (uPA) and its

  year unknowncited by this paper

• A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles

  2025cites this paper
• Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells

  2024cites this paper
• SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment

  2024cites this paper
• Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells

  2024cites this paper
• Advances on Senescence-associated Secretory Phenotype Regulated by Circular RNAs in Tumors.

  2024cites this paper
• Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors.

  2023cites this paper
• Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition

  2023cites this paper
• Suppression of antitumor cytokine IL‑24 by PRG4 and PAI‑1 may promote myxoid liposarcoma cell survival.

  2023cites this paper
• Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis

  2022cites this paper
• SERPINE1 Overexpression Promotes Malignant Progression and Poor Prognosis of Gastric Cancer

  2022cites this paper
• Does Opium Consumption Have Shared Impact on Atherosclerotic Cardiovascular Disease and Cancer?

  2022cites this paper
• Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets

  2022cites this paper
• Evaluation of CEP55, SERPINE1 and SMPD3 genes and proteins as diagnostic and prognostic biomarkers in gastric carcinoma in Egyptian patients

  2022cites this paper
• PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity

  2022cites this paper
• Sustained postoperative plasma elevations of plasminogen activator inhibitor-1 following minimally invasive colorectal cancer resection

  2021cites this paper
• The Plasminogen–Activator Plasmin System in Physiological and Pathophysiological Angiogenesis

  2021cites this paper
• Role of plasminogen activator inhibitor-1 in oral tongue squamous cell carcinoma: An immunohistochemical and in vitro analysis.

  2021cites this paper
• The Role of Circular RNAs in DNA Damage Response and Repair

  2021cites this paper
• Crosstalk between obesity and cancer: a role for adipokines

  2021cites this paper
• Neuronal mimicry generates an ecosystem critical for brain metastatic growth of SCLC

  2021cites this paper
• Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway

  2021cites this paper
• Inhibition of plasminogen activator inhibitor-1 blocks programmed death ligand 1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.

  2021cites this paper
• A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?

  2021cites this paper
• Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells

  2021cites this paper
• Signaling in the Physiology and Pathophysiology of Pancreatic Stellate Cells – a Brief Review of Recent Advances

  2020cites this paper
• Targets for protection and mitigation of radiation injury

  2020cites this paper
• Abordaje de la enfermedad cardiovascular en mujeres con cáncer de mama. Posición de la Asociación Nacional de Cardiólogos de México (ANCAM)

  2020cites this paper
• Schwann Cell Stimulation of Pancreatic Cancer Cells: A Proteomic Analysis

  2020cites this paper
• Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model

  2020cites this paper
• The root bark of Morus alba L. regulates tumor‐associated macrophages by blocking recruitment and M2 polarization of macrophages

  2020cites this paper
• Lupeol suppresses plasminogen activator inhibitor-1-mediated macrophage recruitment and attenuates M2 macrophage polarization.

  2020cites this paper
• Approach to cardiovascular disease in women with breast cancer: a position statement of the National Association of Cardiologists of Mexico (ANCAM)

  2020cites this paper
• PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.

  2019cites this paper
• The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

  2019cites this paper
• Endothelial miR-30c suppresses tumor growth via inhibition of TGF-&bgr;–induced Serpine1

  2019cites this paper
• Autophagy inhibition in 3T3-L1 adipocytes breaks the crosstalk with tumor cells by suppression of adipokine production

  2019cites this paper
• Localization of plasminogen activator inhibitor type 1 and 2 in preimplantation mouse development in vitro

  2019cites this paper
• Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8

  2019cites this paper
• Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance

  2018cites this paper
• SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma

  2018cites this paper
• Evaluation of PAI-1 in endometriosis using a homologous immunocompetent mouse model†

  2018cites this paper
• Combined treatment with benzo[a]pyrene and 1&agr;,25‐dihydroxyvitamin D3 induces expression of plasminogen activator inhibitor 1 in monocyte/macrophage‐derived cells

  2018cites this paper
• Plasminogen activator inhibitor-1 in cancer research.

  2018cites this paper
• Identification of Potential Key Genes Associated With the Pathogenesis and Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis

  2018cites this paper
• Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.

  2018influential citation
• Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma

  2018cites this paper
• Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.

  2017cites this paper
• Endogenous Proteases in Tumoral Progression

  2017cites this paper
• Les biomarqueurs à visée pronostique dans le cancer du sein

  2017cites this paper
• Novel Adipocytokines: Monocyte Chemotactic Protein-1, Plasminogen Activator Inhibitor-1, Chemerin

  2017cites this paper
• The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1

  2017cites this paper
• Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment.

  2017cites this paper
• Estudio del valor pronóstico de serpina e1 y su papel en el crecimiento y la diseminación metastática del carcinoma escamoso de cabeza y cuello

  2017cites this paper
• Diabetes-associated dysregulated cytokines and cancer.

  2016cites this paper
• Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis

  2016cites this paper
• Bilateral ovarian carcinomas differ in the expression of metastasis-related genes

  2016cites this paper
• Etude de la voie d’action intracrine et nucléaire du Fibroblast Growth Factor 1 dans des cellules de type neuronal

  2016cites this paper
• High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells

  2016cites this paper
• Platelets surrounding primary tumor cells are related to chemoresistance.

  2016cites this paper
• uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy

  2016influential citation
• PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients

  2015cites this paper
• Inhibition of SERPINE1 Function Attenuates Wound Closure in Response to Tissue Injury: A Role for PAI-1 in Re-Epithelialization and Granulation Tissue Formation

  2015cites this paper
• Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

  2015cites this paper
• A high-fat diet is associated with altered adipokine production and a more aggressive esophageal adenocarcinoma phenotype in vivo.

  2015cites this paper
• The mechanism and significance of synergistic induction of the expression of plasminogen activator inhibitor-1 by glucocorticoid and transforming growth factor beta in human ovarian cancer cells.

  2015cites this paper
• A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage.

  2015cites this paper
• Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer

  2015cites this paper
• Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity

  2015cites this paper
• Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients

  2015cites this paper
• HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma.

  2015cites this paper
• PAI-1 Leads to G1-Phase Cell-Cycle Progression through Cyclin D3/cdk4/6 Upregulation

  2014cites this paper
• Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma.

  2014cites this paper
• Cell Cycle and Senescence PAI-1 Leads to G 1-Phase Cell-Cycle Progression through Cyclin D 3 / cdk 4 / 6 Upregulation

  2014cites this paper
• miR-30b, Down-Regulated in Gastric Cancer, Promotes Apoptosis and Suppresses Tumor Growth by Targeting Plasminogen Activator Inhibitor-1

  2014cites this paper
• Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors

  2014cites this paper
• The role of cancer stem cells in osteosarcoma

  2014cites this paper
• uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies

  2014cites this paper
• Enhancement of DEN-induced liver tumourigenesis in hepatocyte-specific Lass2-knockout mice coincident with upregulation of the TGF-β1-Smad4-PAI-1 axis.

  2014cites this paper
• Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury

  2014cites this paper
• Serpins promote cancer cell survival and vascular co-option in brain metastasis.

  2014cites this paper
• Serpins for Diagnosis and Therapy in Cancer Therapy

  2013cites this paper
• Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model

  2013cites this paper
• Small Molecule Targeting of PAI-1 Function: A New Therapeutic Approach for Treatment of Vascular Stenosis

  2013cites this paper
• SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis

  2013influential citation
• Small Molecule Therapeutics Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model

  2013cites this paper
• A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles

  year unknowncites this paper
• A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles

  year unknowncites this paper
• A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles

  year unknowncites this paper